Date: 2012-08-02
Type of information: Grant
Company: Summit (UK)
Investors: Technology Strategy Board (UK)
Amount: up to £150,000
Funding type: grant
Planned used: The grant will provide additional support for the development of the Company’s OGA inhibitor programme for the treatment of a group of neurodegenerative diseases called tauopathies
Others:
Therapeutic area: Neurodegenerative diseases
